<DOC>
	<DOCNO>NCT00439608</DOCNO>
	<brief_summary>Cetuximab , Paclitaxel , Carboplatin Radiation Esophageal , Gastroesophageal Junction Gastric Cancer</brief_summary>
	<brief_title>BrUOG-EG-203 Cetuximab , Paclitaxel , Carboplatin Radiation Esophageal , Gastroesophageal Junction Gastric Cancer</brief_title>
	<detailed_description>The primary objective phase II trial estimate rate complete pathologic response determine surgical resection post treatment endoscopy ( patient undergo resection ) treatment regimen test . With total accrual 28 evaluable patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients require pathologically confirm adenocarcinoma squamous cell carcinoma esophagus , gastroesophageal junction , stomach . Patients may mediastinal , celiac adenopathy , periportal regional gastric lymphadenopathy . There must evidence distant organ metastasis . No prior radiation gastric esophageal cancer . Patients must &gt; 18 year age , nonpregnant Patients must ANC &gt; 1,500/ul , platelet &gt; 100,000/ul , creatinine &lt; 2 x upper limit normal ( ULN ) bilirubin &lt; 1.5 x ULN , AST &lt; 3 x ULN . ECOG performance status 02 . Patients must significant infection coexistent medical condition would preclude protocol therapy . Female patient , must either child bear potential negative pregnancy test within 7 day start study treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Pregnant lactating female eligible . All patient must sign informed consent Any follow criterion make patient ineligible participate study : Acute hepatitis AIDS . Active uncontrolled infection . Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . Prior therapy specifically directly target EGFR pathway . Prior severe infusion reaction monoclonal antibody . Any concurrent chemotherapy indicate study protocol investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>gastroesophageal cancer</keyword>
	<keyword>gastric cancer</keyword>
</DOC>